Every 8-K that COGNITION THERAPEUTICS INC (CGTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGTX filings page.
Cognition Therapeutics, Inc. reported second-quarter 2026 results and a business update centered on its lead candidate zervimesine (CT1812) for neurodegenerative disorders. Management highlighted progress in FDA discussions that clarified key elements of a planned Phase 3 trial in dementia with Lewy bodies psychosis, targeted to start in mid-2027 using an improved tablet formulation.
As of June 30, 2026, the company held approximately $34.8 million in cash, cash equivalents and restricted cash, plus $21.6 million in remaining obligated grant funding from the National Institute of Aging, and expects this to fund operations into the fourth quarter of 2027. Second-quarter research and development expenses were $5.1 million, down from $11.5 million a year earlier, while general and administrative expenses were $2.6 million versus $2.5 million. Net loss narrowed to $3.9 million, or $(0.04) per share, compared with $6.7 million, or $(0.11) per share in the prior-year quarter. The company also noted allowance of a new composition-of-matter patent for zervimesine, extending intellectual property protection.
Cognition Therapeutics announced that the FDA provided written feedback aligning on key aspects of a pivotal Phase 3 trial of zervimesine (CT1812) for psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis can be an approvable outcome to support a New Drug Application.
The planned registrational program is expected to begin in mid-2027 and will randomize people with DLB psychosis to receive 100 mg once-daily oral zervimesine or placebo for nine months, including patients on stable off-label antipsychotics. The company is working with the FDA to use the neuropsychiatric inventory (NPI) as a novel primary endpoint.
The study builds on Phase 2 SHIMMER data, where zervimesine showed improvements in psychosis symptoms versus placebo and, in a recent analysis, slowed progression of hallucinations and delusions by 89%. Cognition highlights a significant unmet need, noting that up to 80% of DLB patients experience psychosis and no drugs are currently approved for DLB.
Cognition Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, conducted virtually. Stockholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and until their successors are elected or appointed.
Fletcher received 15,093,537 votes for and 680,677 withheld, while Ricciardi received 15,094,238 votes for and 679,976 withheld, with 34,035,661 broker non-votes for each. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year, with 49,039,407 votes for, 126,951 against, and 643,517 abstentions.
Cognition Therapeutics, Inc. furnished an investor presentation under Regulation FD, outlining its strategy as a clinical-stage CNS drug developer focused on zervimesine (CT1812). The company highlights Dementia with Lewy bodies (DLB) psychosis as its lead indication, with a Phase 3 registrational trial in development following the SHIMMER Phase 2 study.
As of March 31, 2026, Cognition reports approximately $31 million in cash, equivalents and restricted cash, $25 million in obligated NIA grant funds, and a cash runway into Q2 2027 based on its current operating plan. The presentation notes more than $170 million in cumulative NIH/NIA grant support and a workforce of about 14 employees.
The deck describes SHIMMER Phase 2 results in DLB, including slowing of neuropsychiatric decline on the NPI-12 measure versus placebo, and plans for a 9‑month registrational study in DLB psychosis overseen by the FDA’s Division of Psychiatry. It also details Alzheimer’s programs, including the completed SHINE Phase 2 trial and the ongoing 545‑patient START trial in MCI through mild Alzheimer’s disease funded by an $81 million NIA grant.
Cognition Therapeutics reported that it has completed a planned meeting with the U.S. Food and Drug Administration to discuss zervimesine (CT1812) for dementia with Lewy bodies patients with psychosis. The discussion reviewed Phase 2 SHIMMER results and potential design and endpoints for a registrational trial.
The company said the interaction was productive and believes there is a path forward to develop zervimesine for DLB psychosis, with formal FDA meeting minutes expected in June. Zervimesine is an investigational once-daily oral therapy that has shown promise in Phase 2 studies in DLB and mild-to-moderate Alzheimer’s disease.
Cognition noted it has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its neurodegenerative disease research and clinical programs.
Cognition Therapeutics reported first-quarter 2026 results and a business update focused on its lead candidate zervimesine. Cash, cash equivalents and restricted cash were about $31.2 million as of March 31, 2026, with $25.6 million of obligated grant funds remaining, and the company estimates its cash will fund operations through the second quarter of 2027.
Research and development expenses fell to $6.1 million from $10.8 million a year earlier, while general and administrative expenses declined to $2.7 million from $3.0 million. Net loss narrowed to $4.6 million, or $(0.05) per share, compared with $8.5 million, or $(0.14) per share, on higher grant and other income.
The company highlighted a scheduled May 20, 2026 meeting with the FDA’s Division of Psychiatry to discuss a potential registrational study of zervimesine in dementia with Lewy body psychosis and reiterated that topline results from the 545-participant Phase 2 START Alzheimer’s study are anticipated in 2027.
Cognition Therapeutics reported improved 2025 results with a smaller loss and stronger balance sheet while advancing its neurology pipeline. For the year ended December 31, 2025, the company recorded a net loss of $23.5 million, or $(0.32) per share, compared with a net loss of $34.0 million, or $(0.86) per share in 2024.
Research and development expenses fell to $37.2 million from $41.7 million, and general and administrative expenses declined to $10.6 million from $12.3 million, reflecting lower clinical and stock-based compensation costs. Grant income increased to $23.4 million.
Cash, cash equivalents, and restricted cash were $37.0 million as of December 31, 2025, with remaining obligated grant funds of $35.7 million. The company estimates its cash will fund operations and capital spending through the second quarter of 2027. Clinically, it completed enrollment in the Phase 2 START Alzheimer’s study, reported strong Phase 2 SHIMMER data in DLB, launched an expanded access program for DLB, and is planning a mid-2026 FDA Division of Psychiatry meeting to align on a registrational path for zervimesine in DLB psychosis.
Cognition Therapeutics reported that it is advancing development of its oral drug zervimesine (CT1812) as a potential treatment for dementia with Lewy bodies (DLB) psychosis, a condition affecting as many as 75% of DLB patients and with no currently approved therapies.
The company’s plan follows final minutes from an FDA Type C meeting held on January 21, 2026 and is based on Phase 2 SHIMMER data showing zervimesine slowed decline on the 12‑item neuropsychiatric inventory by 86% versus placebo. The next DLB study is intended as a registrational trial focused on neuropsychiatric and behavioral symptoms, randomizing patients to 100 mg zervimesine or placebo with an open‑label extension.
Cognition expects to meet with the FDA Division of Psychiatry by midyear 2026 to discuss the DLB psychosis program. Zervimesine has been generally well tolerated in clinical studies and is also being evaluated in Alzheimer’s disease and other neurodegenerative indications with substantial grant support from the National Institute on Aging.
Cognition Therapeutics, Inc. filed a current report to note that it has issued a press release about completing a Tye C meeting with the U.S. Food and Drug Administration for its drug candidate zervimesine in dementia with Lewy bodies. The company is furnishing this press release as an exhibit to the report, providing investors with an official update on this regulatory interaction.
Cognition Therapeutics established a new at-the-market stock offering program that permits it to sell up to $75,000,000 of common shares through Jefferies as sales agent or principal. Sales, if any, will be made under a prospectus supplement filed on December 18, 2025, and effected as at-the-market transactions or negotiated deals under a Form S-3 registration statement.
The company also terminated its prior at-the-market program started in 2022 with Cantor Fitzgerald and B. Riley, which had authorized up to $40,000,000 of sales and had approximately $12,500,000 of capacity remaining at termination. Cognition Therapeutics incurred no termination penalties and will no longer sell shares under the 2022 program.
Cognition Therapeutics (CGTX) furnished an 8‑K announcing its financial results for the quarter ended September 30, 2025. The company issued a press release on November 6, 2025, and provided it as Exhibit 99.1. The disclosure is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly stated.
The filing lists the company’s common stock on The Nasdaq Stock Market under the symbol CGTX and notes its status as an emerging growth company. Exhibit 104 (the cover page Inline XBRL data) is also included.
Cognition Therapeutics, Inc. (CGTX) filed an 8-K reporting execution of transaction documents on August 27, 2025, with the filing signed on August 28, 2025 by President and CEO Lisa Ricciardi. The filing lists executed exhibits associated with a securities placement, including a Placement Agency Agreement, a Form of Placement Agent Warrant, a Form of Securities Purchase Agreement, and a legal opinion and consent from Goodwin Procter LLP. The cover page interactive XBRL file is included. The filing indicates a financing-related transaction was documented but does not include pricing, amounts, investor identities, or economic terms within the text provided here.
Cognition Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received a Nasdaq deficiency notice on September 12, 2024 because its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days. As of August 25, 2025, the stock had closed above $1.00 per share for more than ten consecutive trading days, satisfying the requirement.
On August 26, 2025, Nasdaq informed Cognition Therapeutics that it now meets the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) and is in compliance with Nasdaq’s listing standards.
Cognition Therapeutics, Inc. (CGTX) filed a Form 8-K to disclose the voting results of its 18 June 2025 virtual Annual Meeting of Stockholders.
- Director elections: Stockholders elected Class I directors Peggy Wallace (8,566,458 FOR; 2,590,981 WITHHELD) and Ellen B. Richstone (8,686,877 FOR; 2,470,562 WITHHELD). Each will serve until the 2028 annual meeting, subject to the usual contingencies. There were 22,760,336 broker non-votes for each nominee.
- Auditor ratification: Ernst & Young LLP was confirmed as the Company’s independent registered public accounting firm for fiscal 2025 with 33,457,921 FOR, 327,242 AGAINST and 132,612 ABSTAIN votes; no broker non-votes were recorded.
No additional proposals or material business developments were reported.